EE04852B1 - C-21 modifitseeritud epotioloonid, nende valmistamise meetod ning kasutamine ja ravimkoostise kasutamine vähkkasvajate või teiste proliferatiivsete haiguste ravimisel - Google Patents

C-21 modifitseeritud epotioloonid, nende valmistamise meetod ning kasutamine ja ravimkoostise kasutamine vähkkasvajate või teiste proliferatiivsete haiguste ravimisel

Info

Publication number
EE04852B1
EE04852B1 EEP200100437A EEP200100437A EE04852B1 EE 04852 B1 EE04852 B1 EE 04852B1 EE P200100437 A EEP200100437 A EE P200100437A EE P200100437 A EEP200100437 A EE P200100437A EE 04852 B1 EE04852 B1 EE 04852B1
Authority
EE
Estonia
Prior art keywords
epothiolones
cancerous
modified
treatment
making
Prior art date
Application number
EEP200100437A
Other languages
English (en)
Estonian (et)
Inventor
Hoefle Gerhard
Glaser Nicole
Leibold Thomas
D. Vite Gregory
Kim Soong-Hoon
Original Assignee
Gesellschaft Fuer Biotechnologische Forschung Mbh
Bristol-Myers Squibb Company
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority claimed from DE1999107588 external-priority patent/DE19907588A1/de
Priority claimed from DE1999130111 external-priority patent/DE19930111A1/de
Application filed by Gesellschaft Fuer Biotechnologische Forschung Mbh, Bristol-Myers Squibb Company filed Critical Gesellschaft Fuer Biotechnologische Forschung Mbh
Publication of EE200100437A publication Critical patent/EE200100437A/xx
Publication of EE04852B1 publication Critical patent/EE04852B1/xx

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D417/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
    • C07D417/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings
    • C07D417/06—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings linked by a carbon chain containing only aliphatic carbon atoms
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/10—Antimycotics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/02—Antineoplastic agents specific for leukemia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/04—Antineoplastic agents specific for metastasis
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D493/00—Heterocyclic compounds containing oxygen atoms as the only ring hetero atoms in the condensed system
    • C07D493/02—Heterocyclic compounds containing oxygen atoms as the only ring hetero atoms in the condensed system in which the condensed system contains two hetero rings
    • C07D493/04—Ortho-condensed systems

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Public Health (AREA)
  • General Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Oncology (AREA)
  • Hematology (AREA)
  • Communicable Diseases (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Heterocyclic Carbon Compounds Containing A Hetero Ring Having Oxygen Or Sulfur (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Saccharide Compounds (AREA)
EEP200100437A 1999-02-22 2000-02-17 C-21 modifitseeritud epotioloonid, nende valmistamise meetod ning kasutamine ja ravimkoostise kasutamine vähkkasvajate või teiste proliferatiivsete haiguste ravimisel EE04852B1 (et)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
DE1999107588 DE19907588A1 (de) 1999-02-22 1999-02-22 C-21 Modifizierte Epothilone
DE1999130111 DE19930111A1 (de) 1999-07-01 1999-07-01 C-21 Modifizierte Epothilone
PCT/US2000/004068 WO2000050423A1 (en) 1999-02-22 2000-02-17 C-21 modified epothilones

Publications (2)

Publication Number Publication Date
EE200100437A EE200100437A (et) 2002-12-16
EE04852B1 true EE04852B1 (et) 2007-06-15

Family

ID=26051995

Family Applications (1)

Application Number Title Priority Date Filing Date
EEP200100437A EE04852B1 (et) 1999-02-22 2000-02-17 C-21 modifitseeritud epotioloonid, nende valmistamise meetod ning kasutamine ja ravimkoostise kasutamine vähkkasvajate või teiste proliferatiivsete haiguste ravimisel

Country Status (37)

Country Link
US (1) US6262094B1 (cs)
EP (1) EP1157023B1 (cs)
JP (1) JP4598957B2 (cs)
KR (1) KR100685336B1 (cs)
CN (1) CN1205208C (cs)
AR (1) AR028815A1 (cs)
AT (1) ATE254615T1 (cs)
AU (1) AU771089B2 (cs)
BG (1) BG64987B1 (cs)
BR (1) BR0008379A (cs)
CA (1) CA2360452C (cs)
CO (1) CO5140093A1 (cs)
CZ (1) CZ301498B6 (cs)
DE (1) DE60006649T2 (cs)
DK (1) DK1157023T3 (cs)
EE (1) EE04852B1 (cs)
ES (1) ES2209831T3 (cs)
GE (1) GEP20033067B (cs)
HK (1) HK1038923B (cs)
HU (1) HUP0200076A3 (cs)
ID (1) ID29829A (cs)
IL (1) IL144501A0 (cs)
LT (1) LT4944B (cs)
LV (1) LV12755B (cs)
MX (1) MXPA01008374A (cs)
MY (1) MY120601A (cs)
NO (1) NO320806B1 (cs)
NZ (1) NZ513629A (cs)
PE (1) PE20001546A1 (cs)
PL (1) PL212545B1 (cs)
PT (1) PT1157023E (cs)
RU (1) RU2253652C2 (cs)
SK (1) SK287200B6 (cs)
TR (1) TR200102401T2 (cs)
TW (1) TWI270546B (cs)
UY (1) UY26024A1 (cs)
WO (1) WO2000050423A1 (cs)

Families Citing this family (76)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE59711647D1 (de) * 1996-11-18 2004-06-24 Biotechnolog Forschung Gmbh Epothilon d, dessen herstellung und dessen verwendung als cytostatisches mittel bzw. als pflanzenschutzmittel
US6867305B2 (en) 1996-12-03 2005-03-15 Sloan-Kettering Institute For Cancer Research Synthesis of epothilones, intermediates thereto and analogues thereof
US6204388B1 (en) * 1996-12-03 2001-03-20 Sloan-Kettering Institute For Cancer Research Synthesis of epothilones, intermediates thereto and analogues thereof
AU756699B2 (en) 1996-12-03 2003-01-23 Sloan-Kettering Institute For Cancer Research Synthesis of epothilones, intermediates thereto, analogues and uses thereof
US6194181B1 (en) * 1998-02-19 2001-02-27 Novartis Ag Fermentative preparation process for and crystal forms of cytostatics
GB9810659D0 (en) * 1998-05-18 1998-07-15 Ciba Geigy Ag Organic compounds
US6780620B1 (en) * 1998-12-23 2004-08-24 Bristol-Myers Squibb Company Microbial transformation method for the preparation of an epothilone
US6589968B2 (en) * 2001-02-13 2003-07-08 Kosan Biosciences, Inc. Epothilone compounds and methods for making and using the same
HUP0302905A3 (en) 2000-09-22 2006-05-29 Biotechnolog Forschung Gmbh Triazolo-epothilone-analogs, process for their preparation and pharmaceutical compositions containing them
WO2002030356A2 (en) * 2000-10-13 2002-04-18 The University Of Mississipi Synthesis of epothilones and relates analogs
SK8552003A3 (en) * 2001-01-25 2004-06-08 Bristol Myers Squibb Co Parenteral formulation containing epothilone analogs
US6893859B2 (en) 2001-02-13 2005-05-17 Kosan Biosciences, Inc. Epothilone derivatives and methods for making and using the same
CN1610549A (zh) * 2001-02-20 2005-04-27 布里斯托尔-迈尔斯斯奎布公司 用于治疗难治肿瘤的埃坡霉素衍生物
JP2004522774A (ja) 2001-02-20 2004-07-29 ブリストル−マイヤーズ　スクイブ　カンパニー エポチロン誘導体を用いる耐性腫瘍の治療
ES2384789T3 (es) * 2001-03-14 2012-07-12 Bristol-Myers Squibb Company Combinación de un análogo de epotilona y agentes quimioterapéuticos para el tratamiento de enfermedades proliferativas
CA2471509A1 (en) * 2002-01-14 2003-07-17 Novartis Ag Combinations comprising epothilones and anti-metabolites
TW200303202A (en) 2002-02-15 2003-09-01 Bristol Myers Squibb Co Method of preparation of 21-amino epothilone derivatives
AU2003212457A1 (en) * 2002-03-01 2003-09-16 University Of Notre Dame Derivatives of epothilone b and d and synthesis thereof
SI1485090T1 (sl) * 2002-03-08 2008-06-30 Novartis Ag Kombinacija vključujoča derivat epotilona in imidazotetrazinon
KR20040101274A (ko) * 2002-03-08 2004-12-02 노파르티스 아게 에포틸론 유도체 및 알킬화제를 포함하는 병용 제제
WO2003077903A1 (en) * 2002-03-12 2003-09-25 Bristol-Myers Squibb Company C12-cyano epothilone derivatives
ATE452896T1 (de) 2002-03-12 2010-01-15 Bristol Myers Squibb Co C3-cyanoepothilonderivate
TW200403994A (en) * 2002-04-04 2004-03-16 Bristol Myers Squibb Co Oral administration of EPOTHILONES
BR0309711A (pt) * 2002-05-01 2005-02-09 Novartis Ag Método para o tratamento de doenças do câncer
TW200400191A (en) * 2002-05-15 2004-01-01 Bristol Myers Squibb Co Pharmaceutical compositions and methods of using C-21 modified epothilone derivatives
US7649006B2 (en) 2002-08-23 2010-01-19 Sloan-Kettering Institute For Cancer Research Synthesis of epothilones, intermediates thereto and analogues thereof
PT1767535E (pt) 2002-08-23 2010-02-24 Sloan Kettering Inst Cancer Síntese de epotilonas, respectivos intermediários, análogos e suas utilizações
US6921769B2 (en) 2002-08-23 2005-07-26 Sloan-Kettering Institute For Cancer Research Synthesis of epothilones, intermediates thereto and analogues thereof
EP2287168B1 (en) * 2002-09-23 2013-02-13 Bristol-Myers Squibb Company Methods for the preparation, isolation and purification of epothilone B, and X-ray crystal structures of epothilone B
MXPA05003706A (es) * 2002-10-09 2005-07-01 Kosan Biosciences Inc Epo d+5-fu/gemcitabina.
ATE479667T1 (de) 2003-02-06 2010-09-15 Bristol Myers Squibb Co Als kinaseinhibitoren geeignete verbindungen auf thiazolylbasis
US20050171167A1 (en) * 2003-11-04 2005-08-04 Haby Thomas A. Process and formulation containing epothilones and analogs thereof
US7420059B2 (en) * 2003-11-20 2008-09-02 Bristol-Myers Squibb Company HMG-CoA reductase inhibitors and method
EP1559447A1 (en) 2004-01-30 2005-08-03 Institut National De La Sante Et De La Recherche Medicale (Inserm) Use of epothilones in the treatment of neuronal connectivity defects such as schizophrenia and autism
GB0405898D0 (en) 2004-03-16 2004-04-21 Novartis Ag Organic compounds
US7459562B2 (en) * 2004-04-23 2008-12-02 Bristol-Myers Squibb Company Monocyclic heterocycles as kinase inhibitors
TW200538453A (en) * 2004-04-26 2005-12-01 Bristol Myers Squibb Co Bicyclic heterocycles as kinase inhibitors
US20090004277A1 (en) * 2004-05-18 2009-01-01 Franchini Miriam K Nanoparticle dispersion containing lactam compound
US7173031B2 (en) 2004-06-28 2007-02-06 Bristol-Myers Squibb Company Pyrrolotriazine kinase inhibitors
US7439246B2 (en) * 2004-06-28 2008-10-21 Bristol-Myers Squibb Company Fused heterocyclic kinase inhibitors
US7432373B2 (en) * 2004-06-28 2008-10-07 Bristol-Meyers Squibb Company Processes and intermediates useful for preparing fused heterocyclic kinase inhibitors
ATE397442T1 (de) * 2004-11-18 2008-06-15 Bristol Myers Squibb Co Magensaftresistent beschichtetes pellet mit ixabepilon
WO2006055742A1 (en) * 2004-11-18 2006-05-26 Bristol-Myers Squibb Company Enteric coated bead comprising epothilone or epothilone analog, and preparation and administration thereof
US7772177B2 (en) 2005-05-18 2010-08-10 Aegera Therapeutics, Inc. BIR domain binding compounds
CA2628227A1 (en) * 2005-11-22 2007-05-31 The Scripps Research Institute Chemical synthesis of a highly potent epothilone
US7348325B2 (en) 2005-11-30 2008-03-25 Bristol-Myers Squibb Company Pyrrolotriazine kinase inhibitors
SG10201407457UA (en) 2006-05-16 2014-12-30 Pharmascience Inc Iap bir domain binding compounds
US20100099090A1 (en) * 2007-03-05 2010-04-22 Bristol-Mayers Squibb Company Biomarkers and methods for determining sensitivity to ctla-4 antagonists
JP2010528115A (ja) * 2007-05-25 2010-08-19 ブリストル−マイヤーズ スクイブ カンパニー エポチロン化合物およびアナログの製造方法
WO2009089260A2 (en) 2008-01-08 2009-07-16 Bristol-Myers Squibb Company Combination of anti-ctla4 antibody with tubulin modulating agents for the treatment of proliferative diseases
EA021758B1 (ru) * 2008-04-24 2015-08-31 Бристол-Маерс Сквибб Компани Способ лечения болезни альцгеймера
US20090311187A1 (en) * 2008-05-29 2009-12-17 Bristol-Myers Squibb Company Methods for predicting patient response to modulation of the Co-stimulatory pathway
US8119129B2 (en) 2008-08-01 2012-02-21 Bristol-Myers Squibb Company Combination of anti-CTLA4 antibody with dasatinib for the treatment of proliferative diseases
LT2769737T (lt) 2009-07-20 2017-06-26 Bristol-Myers Squibb Company Anti-ctla4 antikūno derinys su etopozidu, skirtas sinerginiam proliferacinių ligų gydymui
WO2011049625A1 (en) 2009-10-20 2011-04-28 Mansour Samadpour Method for aflatoxin screening of products
SI2496567T1 (en) 2009-11-05 2018-01-31 Rhizen Pharmaceuticals S.A. Novel benzopyran kinase modulators
AU2011214057B2 (en) 2010-02-12 2016-11-17 Pharmascience Inc. IAP BIR domain binding compounds
US20130064831A1 (en) 2010-05-17 2013-03-14 Bristol-Myers Squibb Company Immunotherapeutic dosing regimens and combinations thereof
WO2011145035A1 (en) 2010-05-17 2011-11-24 Indian Incozen Therapeutics Pvt. Ltd. Novel 3,5-disubstitued-3h-imidazo[4,5-b]pyridine and 3,5- disubstitued -3h-[1,2,3]triazolo[4,5-b] pyridine compounds as modulators of protein kinases
AU2011255647A1 (en) 2010-05-18 2012-11-15 Cerulean Pharma Inc. Compositions and methods for treatment of autoimmune and other diseases
PL2705029T3 (pl) 2011-05-04 2019-04-30 Rhizen Pharmaceuticals S A Nowe związki jako modulatory kinaz białkowych
CN102863474A (zh) 2011-07-09 2013-01-09 陈小平 一类治疗细胞增殖性疾病的铂化合物、其制备方法和应用
CN102993239A (zh) 2011-09-19 2013-03-27 陈小平 离去基团含氨基或烷胺基的丁二酸衍生物的铂类化合物
AU2013239398B2 (en) 2012-03-30 2017-09-07 Rhizen Pharmaceuticals Sa Novel 3,5-disubstituted-3H-imidazo[4,5-b]pyridine and 3,5- disubstituted -3H-[1,2,3]triazolo[4,5-b]pyridine compounds as modulators of C-met protein kinases
EP2924044B1 (en) 2012-11-17 2018-10-31 Beijing Shuobai Pharmaceutical Co., LTD Platinum compound of malonic acid derivative having leaving group containing amino or alkylamino
US9353150B2 (en) 2012-12-04 2016-05-31 Massachusetts Institute Of Technology Substituted pyrazino[1′,2′:1 ,5]pyrrolo[2,3-b]-indole-1,4-diones for cancer treatment
CA2905509A1 (en) 2013-03-15 2014-09-18 Memorial Sloan-Kettering Cancer Center Hsp90-targeted cardiac imaging and therapy
EP3066127A1 (en) 2013-11-06 2016-09-14 Bristol-Myers Squibb Company Immunotherapeutic dosing regimens and combinations thereof
CN107249632A (zh) 2014-12-04 2017-10-13 百时美施贵宝公司 用于治疗癌症(骨髓瘤)的抗cs1与抗pd‑1抗体的组合
BR112017027692A2 (pt) 2015-06-29 2018-10-09 Bristol Myers Squibb Co regimes de dosagem imunoterapêuticos compreendendo pomalidomida e um anticorpo anti-cs1 para tratamento do câncer
CN105153177B (zh) * 2015-09-28 2017-08-08 湖南大学 呋喃并色满肟烯/炔丙基醚及其制备方法与应用
US10918627B2 (en) 2016-05-11 2021-02-16 Massachusetts Institute Of Technology Convergent and enantioselective total synthesis of Communesin analogs
US11932650B2 (en) 2017-05-11 2024-03-19 Massachusetts Institute Of Technology Potent agelastatin derivatives as modulators for cancer invasion and metastasis
US10640508B2 (en) 2017-10-13 2020-05-05 Massachusetts Institute Of Technology Diazene directed modular synthesis of compounds with quaternary carbon centers
US11535634B2 (en) 2019-06-05 2022-12-27 Massachusetts Institute Of Technology Compounds, conjugates, and compositions of epipolythiodiketopiperazines and polythiodiketopiperazines and uses thereof
US12030888B2 (en) 2021-02-24 2024-07-09 Massachusetts Institute Of Technology Himastatin derivatives, and processes of preparation thereof, and uses thereof

Family Cites Families (28)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE301115C (cs)
DE75883C (de) W. schulte in Siegen und F. A. SAPP in Hillnhütten, Kreis Siegen Ofen zur Erzeugung von Cyanammonium
GB8909737D0 (en) * 1989-04-27 1989-06-14 Shell Int Research Thiazole derivatives
DE4138042C2 (de) 1991-11-19 1993-10-14 Biotechnolog Forschung Gmbh Epothilone, deren Herstellungsverfahren sowie diese Verbindungen enthaltende Mittel
DE19639456A1 (de) 1996-09-25 1998-03-26 Biotechnolog Forschung Gmbh Epothilon-Derivate, Herstellung und Mittel
EP0873341B1 (de) 1995-11-17 2003-09-10 Gesellschaft für biotechnologische Forschung mbH (GBF) Epothilonderivate, herstellung und verwendung
DE19542986A1 (de) 1995-11-17 1997-05-22 Biotechnolog Forschung Gmbh Epothilon-Derivate und deren Verwendung
EP0923583A1 (de) 1996-08-30 1999-06-23 Novartis AG Verfahren zur herstellung von epothilonen und zwischenprodukte innerhalb des verfahrens
DE19636343C1 (de) 1996-08-30 1997-10-23 Schering Ag Zwischenprodukte innerhalb der Totalsynthese von Epothilon A und B
DE19645361A1 (de) 1996-08-30 1998-04-30 Ciba Geigy Ag Zwischenprodukte innerhalb der Totalsynthese von Epothilon A und B, Teil II
DE19645362A1 (de) 1996-10-28 1998-04-30 Ciba Geigy Ag Verfahren zur Herstellung von Epothilon A und B und Derivaten
DE59711647D1 (de) * 1996-11-18 2004-06-24 Biotechnolog Forschung Gmbh Epothilon d, dessen herstellung und dessen verwendung als cytostatisches mittel bzw. als pflanzenschutzmittel
US6515016B2 (en) 1996-12-02 2003-02-04 Angiotech Pharmaceuticals, Inc. Composition and methods of paclitaxel for treating psoriasis
AU756699B2 (en) 1996-12-03 2003-01-23 Sloan-Kettering Institute For Cancer Research Synthesis of epothilones, intermediates thereto, analogues and uses thereof
US6380394B1 (en) * 1996-12-13 2002-04-30 The Scripps Research Institute Epothilone analogs
US6441186B1 (en) * 1996-12-13 2002-08-27 The Scripps Research Institute Epothilone analogs
DE19701758A1 (de) 1997-01-20 1998-07-23 Wessjohann Ludgar A Dr Epothilone-Synthesebausteine
DE19707303B4 (de) 1997-02-11 2006-05-11 Mitteldeutsches Bitumenwerk Gmbh Verfahren zur Gewinnung von Mikrowachsen, Paraffinen und Ölen aus Altkunststoffen oder Altkunststoffgemischen
AU736062B2 (en) 1997-02-25 2001-07-26 Gesellschaft Fur Biotechnologische Forschung Mbh Epothilones which are modified in the side chain
DE19713970B4 (de) 1997-04-04 2006-08-31 R&D-Biopharmaceuticals Gmbh Epothilone-Synthesebausteine II - Prenylderivate
WO1998047891A1 (de) 1997-04-18 1998-10-29 Studiengesellschaft Kohle Mbh Selektive olefinmetathese von bi- oder polyfunktionellen substraten in komprimiertem kohlendioxid als reaktionsmedium
DE19821954A1 (de) 1997-05-15 1998-11-19 Biotechnolog Forschung Gmbh Verfahren zur Herstellung eines Epothilon-Derivats
DE19720312A1 (de) 1997-05-15 1998-11-19 Hoechst Ag Zubereitung mit erhöhter in vivo Verträglichkeit
DE19726627A1 (de) 1997-06-17 1998-12-24 Schering Ag Zwischenprodukte, Verfahren zu ihrer Herstellung und ihre Verwendung zur Herstellung von Epothilon
US6384230B1 (en) 1997-07-16 2002-05-07 Schering Aktiengesellschaft Thiazole derivatives, method for their production and use
US7407975B2 (en) 1997-08-09 2008-08-05 Bayer Schering Pharma Ag Epothilone derivatives, method for producing same and their pharmaceutical use
US6498257B1 (en) * 1998-04-21 2002-12-24 Bristol-Myers Squibb Company 2,3-olefinic epothilone derivatives
EP1140928A4 (en) * 1998-12-23 2002-10-02 Bristol Myers Squibb Co MICROBIAL CONVERSION METHOD FOR PRODUCING AN EPOTHILONE

Also Published As

Publication number Publication date
DE60006649D1 (de) 2003-12-24
CN1341114A (zh) 2002-03-20
CN1205208C (zh) 2005-06-08
BG105830A (en) 2002-03-29
AU3234800A (en) 2000-09-14
PE20001546A1 (es) 2001-03-18
HUP0200076A3 (en) 2003-01-28
SK287200B6 (sk) 2010-03-08
NO20014017D0 (no) 2001-08-17
TR200102401T2 (tr) 2001-12-21
PL212545B1 (pl) 2012-10-31
BR0008379A (pt) 2002-09-24
CO5140093A1 (es) 2002-03-22
ATE254615T1 (de) 2003-12-15
LT2001086A (en) 2002-04-25
LV12755A (en) 2001-11-20
GEP20033067B (en) 2003-09-25
DK1157023T3 (da) 2004-03-29
TWI270546B (en) 2007-01-11
HK1038923A1 (en) 2002-04-04
US6262094B1 (en) 2001-07-17
JP2002537395A (ja) 2002-11-05
NO320806B1 (no) 2006-01-30
HUP0200076A2 (hu) 2002-12-28
KR100685336B1 (ko) 2007-02-23
BG64987B1 (bg) 2006-11-30
LT4944B (lt) 2002-08-26
IL144501A0 (en) 2002-05-23
UY26024A1 (es) 2000-09-29
EP1157023B1 (en) 2003-11-19
NO20014017L (no) 2001-10-17
CZ301498B6 (cs) 2010-03-24
PL350179A1 (en) 2002-11-18
ES2209831T3 (es) 2004-07-01
CZ20012991A3 (cs) 2002-01-16
DE60006649T2 (de) 2004-09-30
PT1157023E (pt) 2004-03-31
HK1038923B (en) 2004-03-19
MXPA01008374A (es) 2003-06-06
SK10782001A3 (sk) 2002-03-05
LV12755B (lv) 2002-04-20
KR20010102199A (ko) 2001-11-15
JP4598957B2 (ja) 2010-12-15
CA2360452A1 (en) 2000-08-31
ID29829A (id) 2001-10-11
AU771089B2 (en) 2004-03-11
CA2360452C (en) 2011-07-26
MY120601A (en) 2005-11-30
RU2253652C2 (ru) 2005-06-10
EE200100437A (et) 2002-12-16
NZ513629A (en) 2004-01-30
WO2000050423A1 (en) 2000-08-31
EP1157023A1 (en) 2001-11-28
AR028815A1 (es) 2003-05-28

Similar Documents

Publication Publication Date Title
EE04852B1 (et) C-21 modifitseeritud epotioloonid, nende valmistamise meetod ning kasutamine ja ravimkoostise kasutamine vähkkasvajate või teiste proliferatiivsete haiguste ravimisel
IL144294A0 (en) P53 inhibitors and therapeutic use of the same
IL197903A (en) A pharmacovigilance containing riavirus to treat cell culture disorders and its kit
IL151946A0 (en) 2-substituted 4-heteroaryl-pyrimidines and their use in the treatment of proliferative disorders
EE200200118A (et) Terapeutilised kinasoliini derivaadid, nende valmistamise meetod ning kasutamine
HUP0104867A3 (en) Heterocyclic compounds useful in the treatment of inflammatory diseases, process for their preparation, pharmaceutical compositions comprising thereof and their use
EE05149B1 (et) Biarlkarboksamiidid, meetod nende valmistamiseks, neid sisaldav ravimkoostis ning nende kasutamine ravis
AU2072201A (en) Agents and methods for the treatment of proliferative diseases
EE05109B1 (et) Sulfoonamiidi derivaadid, nende kasutamine meditsiinis ning meetod nende valmistamiseks
EE200100391A (et) Peptidüül-heterotsüklilised ketoonid, nende kasutamine ja farmatseutiline kompositsioon
DE69941996D1 (de) Pharmazeutische zusammenstellung zur verwendung in notbehandlungen und dessen herstellungsverfahren
WO2001049703A3 (en) Substituted sapogenins and their use
EE200100470A (et) Püridopüranoasepiini derivaadid, nende valmistamine ja terapeutiline kasutamine
MY138883A (en) Use of asiatic acid for treatment of cencer
WO2001028494A3 (en) Nordihydroguaiaretic derivatives for use in treatment of tumors
AU2001283285A1 (en) Antimicrobial composition and methods of use in the treatment of disease
EE04490B1 (et) Ühend, selle valmistamise meetod ning kasutamine meditsiinis
WO2001062235A3 (en) A composition comprising camptothecin and a pyrimidine derivative for the treatment of cancer
EE05099B1 (et) Bradkardiaalsete toimeainete kasutamine hpertroofiaga seotud mokardiaalsete haiguste ravimiseks ja ravimikombinatsioonid
AU2001270484A1 (en) Use of bradycardiac substances in the treatment of myocardial diseases associated with hypertrophy and novel medicament combinations
EE200300504A (et) 3,7-diasabitsüklo[3.3.1]preparaadid, nende valmistamise meetod ja nimetatud preparaatide kasutaminesüdame arütmiate profülaktikas või ravis
EE200000333A (et) Eesnäärmevähi ravis kasutatav konjugaat ning farmatseutiline kompositsioon ja selle valmistamismeetod
DE69939075D1 (de) Pharmazeutische Zusammenstellung zur Vorbeugung und Behandlung von mit Zellkrankheiten des Augenhintergrundes zusammenhängenden Krankheiten
GB9923078D0 (en) Sapogenin derivatives and their use
EE200400074A (et) Koostised ning nende kasutamine proliferatiivsetehaiguste raviks

Legal Events

Date Code Title Description
KB4A Valid patent at the end of a year

Effective date: 20071231

KB4A Valid patent at the end of a year

Effective date: 20081231

KB4A Valid patent at the end of a year

Effective date: 20101231